TD Cowen analyst Charles Rhyee initiated coverage of Waystar (WAY) with a Buy rating and $51 price target Waystar is a leading provider of software-as-a-service products for healthcare providers, including patient payments and clearinghouse solutions, the analyst tells investors in a research note. The firm believes the company should benefit from favorable underlying fundamentals, including complex billing processes and rising out-of-pocket patient costs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAY:
- Waystar 12.5M share Secondary priced at $38.75
- Waystar files to sell 12.5M shares of common stock for holders
- Waystar Holding Corp. Expands Board with New Nominations
- Waystar Holding Corp. Receives Buy Rating from Jailendra Singh Amid Strong Q1 2025 Performance and Strategic Growth Initiatives
- Waystar price target raised to $50 from $45 at Truist